What is the 13F Pro Quality Score for TNDM?

13F Pro ranks TANDEM DIABETES CARE INC (TNDM) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TNDM's current score at https://13fpro.ai/research/TNDM (free sign-up required for the full ranking).

Which hedge funds own the most TNDM stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of TNDM include BlackRock,, VOYA INVESTMENT MANAGEMENT, UBS Group AG. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/TNDM as soon as new 13F filings post.

Where does 13F Pro source TNDM data?

All TANDEM DIABETES CARE INC fundamentals and ownership data come directly from SEC EDGAR. TANDEM DIABETES CARE INC files with the SEC under CIK 1438133. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TNDM in?

TANDEM DIABETES CARE INC (TNDM) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is TNDM research updated on 13F Pro?

TNDM's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

TANDEM DIABETES CARE INC(TNDM)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1438133 TNDM stock profile & AI dashboard →

13F Pro Quality Score

34.8/100

Rank #2,177 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

73.8/100

Profitability

13.8/100

Balance Sheet

9.1/100

Earnings Quality

30.0/100

Free Cash Flow

27.0/100

Institutional Flow

42.2/100

Revenue Scale

48.8/100

Dilution Risk

18.0/100

TNDM Stock Analysis & AI Quality Score

AI stock analysis and institutional research for TANDEM DIABETES CARE INC (TNDM), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TNDM at 34.8/100 on a 32-signal composite quality model, placing it at rank #2,177 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (9.1) and profitability (13.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 18.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), TANDEM DIABETES CARE INC reports quarterly revenue of $247.2M, net income of $-20.4M, free cash flow of $4.8M. Top institutional holders of TNDM by reported 13-F value include BlackRock,, VOYA INVESTMENT MANAGEMENT, UBS Group AG, based on the most recent SEC filings. TNDM trades on the Nasdaq exchange and files with the SEC under CIK 1438133. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TNDM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for TANDEM DIABETES CARE INC directly from SEC EDGAR. TANDEM DIABETES CARE INC's 13F Pro composite quality score has ranged between 8 and 61 since 2021, currently 34.8 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about TANDEM DIABETES CARE INC

Quirks, history, and lore behind TNDM — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical device company · small-cap · listed on Nasdaq · headquartered in San Diego, California.
2
The Numbers
Annual revenue in the range of $300–400 million — growing fast but still unprofitable, as is typical for a device maker reinvesting heavily in R&D.
3
The History
Founded in the early 2000s, it set out to drag a clunky, decades-old medical device into the software age — and eventually forced larger rivals to play catch-up.
4
The Secret
Its hardware is practically a smartphone on your body — the pump is controlled via touchscreen and integrates with continuous glucose monitors for near-automated therapy.
5
The Lore
Its flagship device, the t:slim line, is one of the only insulin pumps on the market that can receive software updates remotely — like an over-the-air Tesla update, but for keeping people alive.
6
The Giveaway
This company makes the t:slim X2 insulin pump for people with Type 1 diabetes — slim enough to fit in a pocket, smart enough to talk to your CGM.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$247.2M

Net Income

Q1 2026

$-20.4M

Free Cash Flow

Q1 2026

$4.8M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+7.9% YoY

$1.01BFY 2025

FY21 $702.8MFY22 $801.2MFY24 $940.2MFY25 $1.01B

Net Income

-113.2% YoY

$-204.7MFY 2025

FY21 $15.6MFY22 $-94.6MFY24 $-96.0MFY25 $-204.7M

Operating Income

-88.9% YoY

$-187.3MFY 2025

FY21 $22.7MFY22 $-92.8MFY24 $-99.1MFY25 $-187.3M

EPS (Diluted)

-106.8% YoY

$-3.04FY 2025

FY21 $0.24FY22 $-1.47FY24 $-1.47FY25 $-3.04

Total Assets

-8.9% YoY

$881.1MFY 2025

FY21 $905.1MFY22 $1.05BFY24 $967.7MFY25 $881.1M

Total Debt

-11.1% YoY

$310.0MFY 2025

FY21 —FY22 —FY24 $348.9MFY25 $310.0M

Op. Cash Flow

-140.1% YoY

$-9.7MFY 2025

FY21 $111.4MFY22 $50.5MFY24 $24.2MFY25 $-9.7M

Metric	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$1.01B +7.9%	$940.2M +17.3%	$801.2M +14.0%	$702.8M +40.9%	$498.8M +37.7%	$362.3M
Net Income	$-204.7M -113.2%	$-96.0M -1.5%	$-94.6M -707.7%	$15.6M +145.3%	$-34.4M -38.9%	$-24.8M
Operating Income	$-187.3M -88.9%	$-99.1M -6.8%	$-92.8M -509.9%	$22.7M +384.7%	$-8.0M +52.4%	$-16.7M
EPS (Diluted)	$-3.04 -106.8%	$-1.47 +0.0%	$-1.47 -712.5%	$0.24 +142.9%	$-0.56 -33.3%	$-0.42
Total Assets	$881.1M -8.9%	$967.7M -8.1%	$1.05B +16.3%	$905.1M +26.3%	$716.4M +119.7%	$326.1M
Total Debt	$310.0M -11.1%	$348.9M	—	—	—	—
Operating Cash Flow	$-9.7M -140.1%	$24.2M -52.0%	$50.5M -54.7%	$111.4M +351.4%	$24.7M -41.1%	$41.9M

AI Insight: TNDM Financial Trends

Debt nearly doubled to $602M in Q1 2026 while equity eroded to $132M, sharply worsening an already fragile balance sheet.

• Revenue grew modestly from $222M in Q2 2024 to $247M in Q1 2026, with Q4 peaks of $283M and $290M showing seasonal strength.

• Operating income turned positive at $8M in Q4 2025 — first profitable operating quarter in the dataset — before slipping back to -$17M in Q1 2026.

• Total debt surged from $310M in Q4 2025 to $602M in Q1 2026, a near-doubling in a single quarter.

• Equity collapsed from $263M in Q4 2024 to $132M in Q1 2026, driven by cumulative net losses including a -$131M hit in Q1 2025.

⚠ The $292M debt jump in Q1 2026 with no corresponding equity raise raises immediate questions about leverage sustainability and refinancing risk.

⚠ Operating cash flow remains inconsistent — positive only in Q3 2024, Q4 2024, Q3 2025, and Q4 2025 — limiting self-funding capacity.

⚠ Q4 2025 operating profit of $8M suggests a path to breakeven; whether Q1 2026's -$17M is seasonal or structural needs monitoring.

AI Insight: TNDM Ratio Trends

Tandem's profitability remains deeply negative with D/E surging to 4.54x in Q1 2026, erasing the near-breakeven achieved in Q4 2024 and Q4 2025.

• Operating margin swung from near-breakeven -0.2% in Q4 2024 to -51.6% in Q1 2025, then recovered to +2.9% in Q4 2025 before retreating to -7.0% in Q1 2026.

• D/E ratio has more than tripled from 1.33x in Q4 2024 to 4.54x in Q1 2026, signaling significant balance sheet deterioration.

• ROIC briefly turned positive at 7.1% in Q4 2025 — the only positive reading in the dataset — but collapsed to -9.5% in Q1 2026.

⚠ Q1 seasonality appears severe: Q1 2025 posted -51.6% OpMargin. Monitor whether Q1 2026's -7.0% signals structural improvement or is again distorted.

⚠ D/E spiking to 4.54x in Q1 2026 from 2.00x in Q4 2025 raises refinancing and solvency risk if losses persist.

⚠ Q4 breakeven pattern (Q4 2024: -0.2% OpMargin; Q4 2025: +2.9%) warrants watching — genuine inflection or recurring seasonal fluke.

Get alerted when TNDM's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for TANDEM DIABETES CARE INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TNDM

BlackRock, Inc.
$204.9M10,690,844 sh
VOYA INVESTMENT MANAGEMENT LLC
$119.9M117,415,000 sh
UBS Group AG
$99.3M5,178,570 sh
Sessa Capital IM, L.P.
$90.7M4,730,757 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$76.6M3,993,333 sh
ArrowMark Colorado Holdings LLC
$59.5M3,103,609 sh
VANGUARD CAPITAL MANAGEMENT LLC
$58.3M3,038,919 sh
LINDEN ADVISORS LP
$55.9M54,791,000 sh
STATE STREET CORP
$51.0M2,662,260 sh
DRIEHAUS CAPITAL MANAGEMENT LLC
$44.2M2,304,414 sh

Fund	Value	Shares
BlackRock, Inc.	$204.9M	10,690,844
VOYA INVESTMENT MANAGEMENT LLC	$119.9M	117,415,000
UBS Group AG	$99.3M	5,178,570
Sessa Capital IM, L.P.	$90.7M	4,730,757
VANGUARD PORTFOLIO MANAGEMENT LLC	$76.6M	3,993,333
ArrowMark Colorado Holdings LLC	$59.5M	3,103,609
VANGUARD CAPITAL MANAGEMENT LLC	$58.3M	3,038,919
LINDEN ADVISORS LP	$55.9M	54,791,000
STATE STREET CORP	$51.0M	2,662,260
DRIEHAUS CAPITAL MANAGEMENT LLC	$44.2M	2,304,414

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TNDM on your watchlist

Track score changes the day TANDEM DIABETES CARE INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TNDM a good stock to buy?

13F Pro's AI-powered analysis of TANDEM DIABETES CARE INC (TNDM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TNDM are available on the TNDM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own TNDM?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TNDM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of TANDEM DIABETES CARE INC's investment landscape.